Analyst Research

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aegerion Pharmaceuticals Inc Receives Positive European CHMP Opinion For LOJUXTA (lomitapide) To Treat Homozygous Familial Hypercholesterolemia (HoFH)


Friday, 31 May 2013 07:17am EDT 

Aegerion Pharmaceuticals Inc announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion with a unanimous vote recommending a marketing authorization for LOJUXTA (lomitapide) hard capsules. If approved, LOJUXTA will be indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolemia (HoFH). The European Commission (EC) needs to ratify the positive opinion from CHMP to grant marketing authorization for LOJUXTA in all 27 European Union member countries. A decision is expected from the European Commission in the third quarter of 2013. 

Company Quote

28.47
-0.24 -0.84%
11 Jul 2014